Thelansis' Conference Coverage at ICNMD 2026: From Congress Floor to Client-Ready Insight in 72 Hours

Inside Thelansis's on-the-ground conference coverage model, as run at ICNMD 2026

THE SETTING: ICNMD 2026, FORTEZZA DA BASSO, FLORENCE
Every July, the neuromuscular disease community picks a city and, for a few days, makes it the center of the therapeutic universe. In 2026, that city was Florence. The 19th International Congress on Neuromuscular Diseases (ICNMD) ran from 7 to 11 July at the Fortezza da Basso, a Medicean fortress turned congress centre, drawing over a thousand neurologists, geneticists, pathologists, patient advocates and industry teams from across the world.

For biopharma teams with a stake in Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA) or generalized myasthenia gravis (gMG), ICNMD isn't a conference to attend; it's a conference to win. Competitor readouts, KOL sentiment, and shifting standard-of-care conversations at a single congress like this can shape messaging and forecasting decisions for the rest of the year. That's the gap our conference coverage model is built to close: turning five days of parallel sessions into a same-week, decision-ready read on what actually moved.

Connect with our conference coverage experts to get this same real-time read at your next priority congress: https://thelansis.com/conference-coverage/

HOW WE COVERED IT: THE THELANSIS CONFERENCE COVERAGE MODEL
Good conference intelligence isn't built in the five days of the event; it's built in the five weeks before it and confirmed in the three days after. We run every major congress through the same three-stage model, applied here to ICNMD's DMD, SMA and gMG agenda.

PRE-CONFERENCE
• Kick off planning, assign an onsite team and lock project ownership roughly 5 weeks out
• Map the full scientific programme against tracked KITs/KIQs and flag high-priority DMD, SMA and gMG abstracts
• Run internal alignment calls to prioritize sessions and set the debrief format and timing
• Finalize the pre-conference deck, session tracker and abstract analysis, ready 4-5 days ahead of the event

CONFERENCE
• Hold a pre-conference briefing to reconfirm priorities and open questions across the tracked TAs
• Cover the DMD, gMG and adjacent neuropathy symposia in parallel across a multi-person onsite team
• File daily reports and run daily internal CI huddles to reconcile notes against KITs/KIQs
• Produce a top-line CI summary within 3 days of the congress closing

POST-CONFERENCE
• Score every finding for business impact and complete primary/secondary source checks
• Run a structured debrief to walk through insights and gather feedback for the next cycle
• Log follow-up questions (KBQs) as the starting brief for deeper secondary research
• Close with a best-practices note and an action plan for the next congress

See how this three-stage model applies to your therapeutic area. Request a Thelansis coverage consulting session: https://thelansis.com/conference-coverage/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ICNMD

WHAT ACTUALLY HAPPENED AT THE CONGRESS
ICNMD 2026's agenda gave DMD, gMG and SMA real airtime, and this is the kind of ground our coverage model is built to hold across all three at once.

• DMD - Italfarmaco presented new Phase 3 EPIDYS open-label extension data for givinostat in DMD, including quantitative MRI evidence of reduced fat infiltration and contractile tissue decline, plus interim safety and loss-of-ambulation findings from the OLE.
• gMG - An industry symposium chaired by Prof. Heinz Wiendl examined upstream BAFF/APRIL inhibition as a strategy to target pathogenic B cells in gMG, alongside continued discussion of treatment-decision factors for targeted gMG therapies.
• SMA - A dedicated session addressed the "transforming SMA landscape," with Prof. Eugenio Mercuri framing the unmet needs that persist even where disease-modifying therapy is established and reimbursed.
• Adjacent TA - A well-attended symposium on multifocal motor neuropathy (MMN) and CIDP covered autoantibody- and complement-mediated mechanisms of nerve injury, adjacent territory the client asked us to monitor for pipeline-overlap risk.

None of this was a surprise on its own, pre-conference abstract screening had already flagged each of these sessions as high priority. The value our model adds is in being in the room for all of them simultaneously, and in turning five days of parallel sessions into one coherent narrative within the same week.
Need this level of competitive detail from your next congress? Connect with us for coverage consulting : https://thelansis.com/conference-coverage/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ICNMD

THE KIND OF SIGNAL OUR TEAMS ARE TRAINED TO CATCH

• Competitive positioning - New OLE-stage data of the kind presented in DMD this year can shift competitor messaging from "slows decline" toward measurable functional and imaging-based improvement, a framing shift that changes how a competing asset needs to be positioned, not just acknowledged.
• Mechanism watch - Upstream BAFF/APRIL inhibition is emerging as a distinct mechanistic lane in gMG, separate from FcRn and complement inhibition, the kind of nuance that earns a dedicated slide in a competitive landscape update rather than a footnote.
• Unmet need signal - Even where a therapy is established and reimbursed, as in SMA, KOL commentary can still surface real gaps in adult and later-onset care, a signal worth tracking for where unmet-need messaging still has room to work.
• Sentiment on the ground - Corridor conversation and industry-theatre traffic often say as much as the main-stage agenda; our onsite teams are trained to read that sentiment and log it as a follow-up question for secondary research, not let it evaporate after the event.

Every insight is tagged back to the KIT/KIQ it answers, so a client's brand and forecasting teams can act on the debrief deck directly instead of digging through raw notes.

WHY THE MODEL WORKS
Applied at ICNMD 2026, this model produced a same-week, decision-ready readout across DMD, gMG and SMA, not a stack of session summaries to sort through later. The structured debrief feeds directly into a client's competitive landscape and forecasting updates, and the KBQs logged on-site become the starting brief for the secondary research that follows.
That's the point of the process: conference coverage isn't a five-day sprint, it's a five-week discipline that happens to have five very busy days in the middle.

Ready to turn your next congress into decision-ready intelligence? Connect with our conference coverage experts: https://thelansis.com/conference-coverage/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ICNMD

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.